ReviewEuropean journal of clinical pharmacology2021
Strategies to prevent drug incompatibility during simultaneous multi-drug infusion in intensive care units: a literature review.
Review in European journal of clinical pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Detection of intravenous drug physicochemical incompatibilities in clinical practice: e-Harvis compared to reference tools.European journal of clinical pharmacology · 2026Observational
- Stability and compatibility of phentolamine mesylate combined with furosemide in common infusion solutions for pediatric critical care.Frontiers in pediatrics · 2026Article
- Compatibility and Stability Study of Butorphanol, Nicardipine, Urapidil, and Tirofiban During Multidrug Simultaneous Infusion.Drug design, development and therapy · 2026Article
- Drug Incompatibilities and Complex Assemblies: Let Us Remain Vigilant!Pharmaceuticals (Basel, Switzerland) · 2025Article
- Evaluation of the Impact of Infusion Set Design on the Particulate Load Induced by Vancomycin-Piperacillin/Tazobactam Incompatibility.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Physicochemical Compatibility of Ceftolozane-Tazobactam with Parenteral Nutrition.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Evaluation of Strategies for Reducing Vancomycin-Piperacillin/Tazobactam Incompatibility.Pharmaceutics · 2023Article
- Nursing strategies for the mechanically ventilated patient.Frontiers in veterinary science · 2023Review
- Drug compatibility with various closed intravenous infusion containers.Frontiers in pharmacology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDrug protocols in intensive care units may require the concomitant administration of many drugs as patients' venous accesses are often limited. A major challenge for clinicians is to limit the risk of simultaneously infusing incompatible drugs. Incompatibilities can lead to the formation of particles and inactivation of drugs, whose consequences on the body have already been indicated. Our objective was to assess current strategies to counter the risk of incompatible infusions and control the resulting clinical consequences.
methodsThis review was independently conducted by three investigators in respect of the PRISMA statement. Three online databases were consulted. Full-text articles, notes, or letters written in English or French, published or in press between the 1990s and the end of February 2020, with clinical study design, were eligible. Parameters of interest were mainly number and size of particles, and a number of observed/avoided incompatibilities.
resultsAll in all, 382 articles were screened, 17 meeting all the acceptance criteria. The strategies outlined and assessed were filtration, the use of multi-lumen devices, the purging of infusion lines, incompatibility tables and databases, and the use of standard operating procedures.
conclusionAlthough many strategies have been developed in recent years to address drug incompatibility risks, clinical data is still lacking. All studies with in vitro design were excluded although some current innovative strategies, like niosomes, should be considered and studied by means of clinical data in the future.
Indexed as
Identifiers
33768303What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.